The increased incidence of diabetic foot ulcers and other target wounds, the availability of reimbursement in developed nations, and the expanding number of burn patients are all driving market expansion. During the projected period, however, the high cost of enzymatic products is expected to limit market growth to some extent.
[Report of 131 Pages] The wound debridement market is expected to develop at a CAGR of 7.2 percent from USD 822 million in 2020 to USD 1,162 million in 2025.
Download PDF Brochure:
During the projection period, the ultrasonic debridement products segment is expected to increase the most.
The wound debridement market is divided into enzymatic, autolytic, mechanical, surgical, ultrasonic, and other categories based on product. During the projection period, the ultrasonic debridement products segment is predicted to increase at the fastest rate. This is due to factors such as their excellent debriding efficacy and accuracy (less of injury to good tissue) during debridement.
In 2019, hospitals held the highest proportion of the wound debridement market by end user.
The wound debridement market has been divided into hospitals, clinics, and other end users based on end-user. The hospitals sector held the greatest market share in 2019. The presence of competent individuals and the availability of infrastructure are the primary driving factors for this market.
The largest regional market for wound debridement is North America.
The wound debridement market has been divided into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). Wound debridement is most popular in North America, followed by Europe. The rising prevalence of diabetes, high penetration of enzymatic debridement solutions, and strong market player presence are all factors driving growth in the North American market. During the projected period, however, Asia Pacific is expected to have the greatest CAGR. The presence of a big patient population and growing awareness of innovative healthcare goods are driving growth in this region.
Key Market Players
Prominent players in the wound debridement market include Smith & Nephew (UK), B. Braun Melsungen AG (Germany), Coloplast (Denmark), ConvaTec (UK), Mölnlycke Healthcare (Sweden), Lohmann & Rauscher (Germany), Integra Lifesciences (US), Arobella Medical, LLC (US), Advancis Medical (UK), RLS Global (Sweden), DeRoyal Industries (US), Sanara MedTech Inc. (US), and EZ Debride (US).
Clinical Trials Market